Posted by Michael Wonder on 02 Mar 2021
Merck provides update on Keytruda (pembrolizumab) indication in metastatic small cell lung cancer in the US
1 March 2021 - Merck today announced the company is voluntarily withdrawing the US indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
The withdrawal of this indication was done in consultation with the US FDA, and Merck is working to complete this process over the coming weeks.
This decision does not affect other indications for Keytruda, Merck’s anti-PD-1 therapy.
